Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company’s biosensor platform has the potential to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. The Company’s current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
Company profile
Ticker
INBS
Exchange
Website
CEO
Harry Simeonidis
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GBS Inc., Glucose Biosensor Systems (Greater China) Holdings, Inc.
SEC CIK
Corporate docs
Subsidiaries
Intelligent Bio Solutions (APAC) Pty Ltd • GBS Operations Inc. • Intelligent Fingerprinting Limited ...
IRS number
821512711
INBS stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
12 Apr 24
8-K
Regulation FD Disclosure
9 Apr 24
424B3
Prospectus supplement
28 Mar 24
EFFECT
Notice of effectiveness
28 Mar 24
D
$10.10 mm in equity / options, sold $10.10 mm, 8 investors
22 Mar 24
S-3
Shelf registration
18 Mar 24
424B3
Prospectus supplement
18 Mar 24
EFFECT
Notice of effectiveness
18 Mar 24
8-K
Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
12 Mar 24
S-3
Shelf registration
4 Mar 24
Transcripts
INBS
Earnings call transcript
2023 Q1
12 Nov 22
INBS
Earnings call transcript
2022 Q4
1 Sep 22
INBS
Earnings call transcript
2022 Q3
15 May 22
INBS
Earnings call transcript
2022 Q2
11 Feb 22
INBS
Earnings call transcript
2022 Q1
12 Nov 21
INBS
Earnings call transcript
2021 Q4
12 Aug 21
INBS
Earnings call transcript
2021 Q4
11 Aug 21
Latest ownership filings
4
Spiro Kevin Sakiris
21 Mar 24
SC 13G/A
Ionic Ventures, LLC
14 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G/A
Bigger Capital, LLC
5 Feb 24
SC 13G
Lind Global Fund II LP
20 Oct 23
SC 13G
Lind Global Fund II LP
10 Oct 23
4/A
Spiro Kevin Sakiris
10 Oct 23
4
CHRISTOPHER TOWERS
6 Oct 23
4
Spiro Kevin Sakiris
6 Oct 23
SC 13G
BIGGER CAPITAL FUND L P
4 Oct 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 186.40 k | 186.40 k | 186.40 k | 186.40 k | 186.40 k | 186.40 k |
Cash burn (monthly) | 450.28 k | 463.02 k | 842.12 k | 1.16 mm | 437.28 k | 566.29 k |
Cash used (since last report) | 2.98 mm | 3.07 mm | 5.58 mm | 7.67 mm | 2.90 mm | 3.75 mm |
Cash remaining | -2.80 mm | -2.88 mm | -5.39 mm | -7.48 mm | -2.71 mm | -3.56 mm |
Runway (months of cash) | -6.2 | -6.2 | -6.4 | -6.5 | -6.2 | -6.3 |
Institutional ownership, Q2 2023
18.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 1 |
Closed positions | 2 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 9.45 mm |
Total shares | 513.29 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Gary W. Rollins Foundation | 213.27 k | $595.00 k |
IOI Ionic Ventures | 148.50 k | $443.00 k |
Lind Global Fund II | 148.50 k | $0.00 |
Tower Research Capital | 3.03 k | $8.41 mm |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Mar 24 | Spiro Kevin Sakiris | Common Stock | Acquire X | Yes | No | 0 | 9,394 | 0.00 | 19,180 | |
20 Mar 24 | Spiro Kevin Sakiris | Common Stock Warrants (Series F) Common Stock | Dispose X | Yes | No | 0 | 9,394 | 0.00 | 0 | |
4 Oct 23 | Spiro Kevin Sakiris | Common Stock | Buy | Acquire P | Yes | No | 0 | 112,727 | 0.00 | 117,427 |
4 Oct 23 | Spiro Kevin Sakiris | Common Stock Warrants (Series F) Common Stock | Buy | Acquire P | Yes | No | 0 | 112,727 | 0.00 | 112,727 |
4 Oct 23 | Spiro Kevin Sakiris | Common Stock Warrants (Series E) Common Stock | Buy | Acquire P | Yes | No | 0 | 112,727 | 0.00 | 112,727 |
4 Oct 23 | Christopher Towers | Common Stock | Buy | Acquire P | No | No | 0 | 9,090 | 0.00 | 9,880 |
4 Oct 23 | Christopher Towers | Common Stock Warrants (Series F) Common Stock | Buy | Acquire P | No | No | 0 | 9,090 | 0.00 | 9,090 |
4 Oct 23 | Christopher Towers | Common Stock Warrants (Series E) Common Stock | Buy | Acquire P | No | No | 0 | 9,090 | 0.00 | 9,090 |
1 Sep 23 | Harry Simeonidis | Common Stock, par value $0.01 per share | Buy | Acquire P | No | No | 1.85 | 50 | 92.50 | 4,180 |
31 Aug 23 | Harry Simeonidis | Common Stock, par value $0.01 per share | Buy | Acquire P | No | No | 1.92 | 100 | 192.00 | 4,130 |
News
Looking Into Intelligent Bio Solutions's Recent Short Interest
5 Apr 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
8 Mar 24
Peering Into Intelligent Bio Solutions's Recent Short Interest
6 Mar 24
Intelligent Bio Solutions Partners With Cliantha Research To Conduct Clinical Study As Part OOf FDA 510(k) Pathway
28 Feb 24
Peering Into Intelligent Bio Solutions's Recent Short Interest
19 Feb 24
Press releases
Intelligent Bio Solutions Subsidiary Broadens Intellectual Property Portfolio with Grant of New European Patent with Unitary Effect for Innovative Intelligent Fingerprinting DSR-Plus Cartridge Reader
11 Apr 24
Stocks to Watch for Short Squeeze Potential: DJT, INBS, IMPP, HUBC, XXII
10 Apr 24
Ladenburg Thalmann, Esteemed Wall Street Long-Standing Stalwart Since 1876, Advocates 'Buy' for Intelligent Bio, Precision Bio, and More: VTAK, INBS, LASE, MYMD, RVSN
9 Apr 24
Reddit Inc. (NYSE: RDDT) Surges, Uncovering Undervalued Opportunities: DYAI, INBS, MESO, VTAK
28 Mar 24
Trump Media (NASDAQ: DJT) Soars 24%: Opens at $71.93, Ignites Market Buzz Among DYAI, INBS, VTAK
28 Mar 24